Inclisiran lowers LDL-C in ORION-11, clearing first Phase III hurdle

Data showing whether Medicines Co.'s inclisiran has more than a dosing advantage over anti-PCSK9 mAbs will come next week as the biotech reported top-line results Monday.

The Medicines Co. (NASDAQ:MDCO) said the siRNA against PCSK9 met the primary and secondary

Read the full 392 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE